On March 19, 2025, Morimatsu and Siemens signed a strategic cooperation agreement in Shanghai. This cooperation marks a multi-level and multi-field deep collaboration between the two parties in the digital factory and intelligent manufacturing sectors of the pharmaceutical industry, with Morimatsu officially becoming a Siemens Certified Digitalization Value Partner (DVP). Ms. Wang Ailian, General Manager of the PA Engineering Center of Siemens Digital Industries Group, Mr. Meng Wei, Director of the Pharmaceutical Industry, Mr. Jiang Pei, Senior Vice President of Morimatsu LifeSciences, and Mr. Zhuo Jian, along with relevant leaders, attended the ceremony.

Receiving the Siemens Certified Digitalization Value Partner (DVP) certificate indicates that Morimatsu already possesses strong capabilities in the engineering design and integration of Siemens' MES, WMS, DMS, and other digital products.

Siemens is a leading supplier of advanced industrial automation products and software worldwide, providing a robust platform for achieving fully integrated automation solutions and digital manufacturing. Siemens' mature digital solutions can help the pharmaceutical industry improve efficiency, quality, and productivity.

Morimatsu empowers lifecycle value through its MVP Solutions & Service model, committed to providing customers with overall engineering design and operation & maintenance solutions based on digital twin technology. It is the first in the industry to practice the EPCOO concept, collaborating with customers to build digital factories and offering full-lifecycle digital services, including scheme design, project delivery, and later-stage operation & maintenance, creating a "twin-star" of factories and software.

In recent years, Morimatsu has delivered numerous projects for biopharmaceutical customers adopting Siemens' PCS7+BATCH fully integrated automation solutions and has successfully carried out digital and intelligent operation & maintenance planning, layout, implementation, and management enhancement (including MES, EAM, etc.) for multiple customers, helping them achieve full-process automation control of their processes and continuously deepening technological integration and application in automation and informatization fields.

According to the strategic cooperation agreement, Morimatsu and Siemens have established a good cooperative relationship over the years. Building on this foundation, the two parties will engage in closer technological cooperation focused on promoting digitalization in the pharmaceutical industry. Siemens will collaborate deeply with Morimatsu, providing digital products and services such as MES, WMS, and DMS, to assist Morimatsu in accelerating technological integration and innovation breakthroughs, offering more competitive digital solutions to customers in the pharmaceutical industry.

This strategic cooperation is another important milestone in the collaborative innovation of advantages and resources between Morimatsu and Siemens, building on the successful implementation of Industry 4.0. Relying on their profound accumulation and practical experience in the field of industrial automation, Morimatsu and Siemens will empower each other, jointly develop digital solutions, and drive the pharmaceutical industry towards greater efficiency, intelligence, and lower carbon emissions, jointly exploring new models for the construction of intelligent pharmaceutical factories.

Ms. Wang Ailian, General Manager of the PA Engineering Center of Siemens Digital Industries Group, stated:
Morimatsu has been deeply involved in the pharmaceutical industry for many years, possessing profound industry know-how. Siemens leverages its advantages in automation, digitalization, and intelligence to create transformation paths for the industry. Siemens and Morimatsu will delve into industry scenarios, empowering the upgrading of the pharmaceutical industry through the dual drivers of digitalization and decarbonization, crafting unique solutions for the pharmaceutical industry, assisting customers in breaking through efficiency and sustainability bottlenecks, and jointly shaping new industry benchmarks.

Mr. Jiang Pei, Senior Vice President of Morimatsu LifeSciences, stated:
The strategic cooperation between Siemens and Morimatsu demonstrates the complementary advantages of both parties in core technologies, industrial resources, and market layout. We will continue to seek more cooperation areas and models to lay a solid foundation for assisting pharmaceutical enterprises in digital and intelligent transformation, improving the reliability, certainty, and efficiency of research and development, clinical trials, and commercialization, and creating a new ecosystem for smart pharmaceuticals.

About Siemens (China) Co., Ltd.



Siemens is a technology enterprise focusing on the fields of industry, infrastructure, transportation, and healthcare, committed to continuously driving innovation to create a better every day. By integrating the real and digital worlds, Siemens empowers customers to accelerate digital and sustainable transformation, helping factories become more efficient, cities more livable, and transportation more sustainable.

About Morimatsu LifeSciences



Morimatsu LifeSciences, one of the key business segments of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), serves the pharmaceuticals, bio-pharmaceutical, cosmetic medicine, FMCG (cosmetics, baby, women & home Care, health care, fabric & home care, food, beverage, nutraceuticals) and other industries, providing customers with "core equipment + value-added services + digital intelligence integrated plant solutions and services" ("MVP Solutions & Services"), focusing on core equipment, stainless steel process systems, disposable process systems, consumables, laboratory solutions, digital and modular plant solutions and services. 

Forward-Looking Statements

The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of "predicted", "believed", "forecast", "planned" and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our Company undertakes no obligation to constantly revise such predicted statements.

Forward-looking statements are based on our Company management's current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guarantees of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our Company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.